Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Nanoform Finland Oyj (NANOFS) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Nanoform Finland Oyj SEK 2.01, price SEK 9.40, upside -78.6%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
NF
Thin data
Sep 24, 2026
Nanoform Finland Oyj
NANOFS · STWeakest SetupStrongly overvalued and low quality.
!Fair value kr 2.01 · Strongly overvalued (−78.6%)
!Quality 50/100
!Mixed Growth (revenue 5y +38.9 %/yr)
!Low debt · negative free cash flow
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch Nanoform Finland Oyj for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 4.50 – kr 83.50 · fair‑value band kr 1.33 – kr 2.52 · the kr 9.40 price screens above the kr 2.01 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States.
Show more
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosage forms of Nanoparticles. It also offers STARMAP, an AI platform predicts the performance of your molecule in Nanoform's technology. The company was founded in 2008 and is headquartered in Helsinki, Finland.
Stock analysis
Nanoform Finland Oyj (NANOFS) currently trades at kr 9.40, while our model-based Fair Value estimate is kr 2.01, 78.6% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 1.33 (bear) to kr 2.52 (bull), the price of kr 9.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Nanoform Finland Oyj reported revenue of €3.5M in FY2025 versus €2.0M in FY2021, a compound +16.1%/yr. Reported net income was −€17.9M in FY2025.
Key figures
Market cap 805M SEK (≈ $80.2M) · EPS (TTM) kr −2.11 · Net margin −295% · Return on equity −33.7% · Return on assets (EBIT) −28.4% · Operating margin −263% · Revenue (TTM) €5.4M · Revenue growth (YoY) +45.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 109% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −79%, NANOFS screens richer than that median.
Fair Value models
Bear kr 1.33
Fair Value kr 2.01
Bull kr 2.52
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham)
kr 2.82
kr 3.78
kr 5.64
54
All 1 models by family
Asset-Based
NCAV (Graham)
kr 2.82
kr 3.78
kr 5.64
54
Notify me when NANOFS reaches fair value
Put NANOFS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
50/100
Of which business quality 51 · Market factors (momentum, volatility) 44
Profitability
2
Margins and returns on capital today
Quality Growth
82
Are margins and returns improving?
Cashflow
11
Earnings quality: real cash, not paper profit
Fin. Strength
100
Balance sheet, leverage, solvency risk
Investment
67
Disciplined investing over empire-building
Low Volatility
40
Calm price path (market factor)
Momentum
57
Price trend over the last 3–12 months (market factor)
52W Momentum
27
Distance to the 52-week high (market factor)
Net Issuance
65
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+27.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.9%
’17
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,828.2% (2020) → −585.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Compare Nanoform Finland Oyj with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 623 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Valuation of the Sweden market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Nanoform Finland Oyj (NANOFS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 2.01 versus a price of kr 9.40, about −79% upside (overvalued).
What is the fair value of NANOFS?
Our model-based fair value for Nanoform Finland Oyj is kr 2.01 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 9.40.
What is the quality score of NANOFS?
Nanoform Finland Oyj has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nanoform Finland Oyj (NANOFS)?
Our model-based price target is the fair value of kr 2.01 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 1.33, optimistic scenario kr 2.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Nanoform Finland Oyj stock forecast for 2026?
Our models put fair value at kr 2.01, about −79% upside versus a price of kr 9.40 (overvalued). Cautious scenario kr 1.33, optimistic scenario kr 2.52. The calculation is refreshed regularly with new filings.
What is the revenue of Nanoform Finland Oyj (NANOFS)?
Nanoform Finland Oyj reported trailing-twelve-month revenue of about €5.4M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Nanoform Finland Oyj (NANOFS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanoform Finland Oyj it is kr 2.01 per share (as of Sep 24, 2026), against a price of kr 9.40. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Nanoform Finland Oyj stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NANOFS trades above its calculated fair value: price kr 9.40, fair value kr 2.01, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NANOFS?
No. The price is what the market pays today (kr 9.40); the fair value is what the company's own numbers justify (kr 2.01). For Nanoform Finland Oyj the two are kr 7.39 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nanoform Finland Oyj worth?
The market values Nanoform Finland Oyj at about 805M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 9.40; our models calculate a fair value of kr 2.01 per share.
What do the bullish and bearish scenarios say about NANOFS?
Our models span a range for Nanoform Finland Oyj: cautious scenario kr 1.33, base kr 2.01, optimistic kr 2.52 per share (as of Sep 24, 2026, price kr 9.40). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nanoform Finland Oyj (NANOFS)?
Balance-sheet figures for Nanoform Finland Oyj (as of Sep 24, 2026): return on equity −33.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is NANOFS from its 52-week high?
Nanoform Finland Oyj trades at kr 9.40, about 30% below its 52-week high of kr 13.50 and 109% above the low of kr 4.50 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 2.01 is for.
Which stocks are comparable to Nanoform Finland Oyj?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nanoform Finland Oyj stock attractive at the current price?
The data as of Sep 24, 2026: price kr 9.40, calculated fair value kr 2.01 (−79%), Quality Score 50/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NANOFS calculated?
We run Nanoform Finland Oyj through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 2.01, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Nanoform Finland Oyj itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nanoform Finland Oyj (NANOFS)?
The closing price on Oct 2, 2026 was kr 9.40. Our model-based fair value is kr 2.01, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nanoform Finland Oyj right now?
The price sits above even our optimistic bull case (kr 2.52). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 1.33 to kr 2.52) leaves room in how you read the outcome.
Key figures of Nanoform Finland Oyj
How large is the market capitalisation of Nanoform Finland Oyj (NANOFS)?
The market capitalisation of Nanoform Finland Oyj is 805M SEK (≈ $80.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Nanoform Finland Oyj (NANOFS)?
Earnings per share at Nanoform Finland Oyj are kr −2.11. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Nanoform Finland Oyj (NANOFS)?
The net margin of Nanoform Finland Oyj is −295% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nanoform Finland Oyj (NANOFS)?
The return on equity (ROE) of Nanoform Finland Oyj is −33.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nanoform Finland Oyj (NANOFS)?
On an EBIT basis the return on assets of Nanoform Finland Oyj is −28.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nanoform Finland Oyj (NANOFS)?
The operating margin of Nanoform Finland Oyj is −263% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nanoform Finland Oyj (NANOFS)?
Revenue at Nanoform Finland Oyj is growing +45.4% versus a year earlier (3y avg +0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Nanoform Finland Oyj (NANOFS) generate?
The free cash flow of Nanoform Finland Oyj is −€18.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Nanoform Finland Oyj (NANOFS) carry?
The net debt of Nanoform Finland Oyj is €343K (fiscal year 2017). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Nanoform Finland Oyj in the live analysis
One click puts Nanoform Finland Oyj on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.